Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection
February 25, 2021 16:00 ET
|
Assembly Biosciences, Inc.
- Prioritizing next generation, more potent core inhibitors, triple combinations with complementary mechanisms of action, and expanding research programs to advance multiple candidates against novel...
Assembly Bio Announces Upcoming Investor Events
February 19, 2021 08:00 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 05, 2021 17:00 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences to Wind-Down Microbiome Program
December 08, 2020 16:02 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2020 16:30 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing
November 17, 2020 08:00 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences and Door Pharmaceuticals Sign Collaboration and Option Agreement to Develop a Novel Class of HBV Core Protein Modulators
November 16, 2020 08:00 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Door Pharmaceuticals, LLC today announced that the companies have signed an exclusive,...
Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster Sessions at the 2020 AASLD The Liver Meeting Digital Experience™
November 13, 2020 08:00 ET
|
Assembly Biosciences, Inc.
- Data show longer-term, differentiated safety profile of vebicorvir and the importance of HBV pregenomic (pg) RNA as a key biomarker, as well as highlight Assembly Bio’s core inhibitor clinical...
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 06, 2020 16:30 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Reports Third Quarter 2020 Financial Results and Business Update
November 05, 2020 16:02 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...